{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:18Z","timestamp":1792057698622,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["26Z9081"],"award-info":[{"award-number":["26Z9081"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00463774"],"award-info":[{"award-number":["RS-2024-00463774"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmc.2026.118821","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:22:39Z","timestamp":1791588159000},"page":"118821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Recent discoveries of CRBN-binding molecular glue degraders: Focus on protein kinases"],"prefix":"10.1016","volume":"144","author":[{"given":"Injeoung","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooyoung","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118821_bb0005","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1021\/acs.chemrev.5c00800","article-title":"Methods to study the molecular mechanism and drive the design of protein degraders","volume":"126","author":"Crowe","year":"2026","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2026.118821_bb0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118821_bb0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2026.118821_bb0020","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","article-title":"Molecular glues for protein-protein interactions: progressing toward a new dream","volume":"31","author":"Konstantinidou","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2026.118821_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.bmc.2026.118821_bb0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-025-01316-z","article-title":"Induced proximity-based therapeutic modalities","volume":"25","author":"King","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118821_bb0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0040","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bmc.2026.118821_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0055","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in duane radial ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2026.118821_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41586-022-05333-5","article-title":"The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron","volume":"610","author":"Ichikawa","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0065","article-title":"Synthetic and medicinal chemistry perspectives on cereblon-binding molecular glue degraders: recent advances and emerging trends","volume":"29","author":"Won","year":"2026","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117683","article-title":"Crbn-based molecular glues: breakthroughs and perspectives","volume":"104","author":"An","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/OTT.S398118","article-title":"The role of CELMoD agents in multiple myeloma","volume":"18","author":"van de Donk","year":"2025","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bmc.2026.118821_bb0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41586-025-09994-w","article-title":"Identification of an allosteric site on the E3 ligase adapter cereblon","volume":"651","author":"Dippon","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130193","article-title":"Design, synthesis, and evaluation of a novel protein degrader FPFT-2216","volume":"123","author":"Ueda","year":"2025","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118821_bb0105","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1038\/s41467-020-18488-4","article-title":"Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide","volume":"11","author":"Furihata","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0115","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1021\/acs.jmedchem.4c02415","article-title":"Development of potent and selective CK1\u03b1 molecular glue degraders","volume":"68","author":"Geng","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0120","doi-asserted-by":"crossref","first-page":"31433","DOI":"10.1021\/jacs.4c06127","article-title":"Discovery of CRBN-dependent WEE1 molecular glue degraders from a multicomponent combinatorial library","volume":"146","author":"Razumkov","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2026.118821_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/science.adt6736","article-title":"Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition","volume":"389","author":"Petzold","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0130","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1038\/s41467-025-62099-w","article-title":"Unveiling the hidden interactome of CRBN molecular glues","volume":"16","author":"Baek","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0135","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chembiol.2025.06.005","article-title":"A cereblon-based glue degrader of NEK7 regulates NLRP3 inflammasome in a context-dependent manner","volume":"32","author":"Sylvain","year":"2025","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2026.118821_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-9-23","article-title":"The secret life of kinases: functions beyond catalysis","volume":"9","author":"Rauch","year":"2011","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.bmc.2026.118821_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.str.2015.10.020","article-title":"Structural basis for the non-catalytic functions of protein kinases","volume":"24","author":"Kung","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.bmc.2026.118821_bb0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-024-44698-1","article-title":"Selective CK1\u03b1 degraders exert antiproliferative activity against a broad range of human cancer cell lines","volume":"15","author":"Nishiguchi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ccell.2023.02.010","article-title":"Dual IKZF2 and CK1\u03b1 degrader targets acute myeloid leukemia cells","volume":"41","author":"Park","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118821_bb0155","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1021\/acsmedchemlett.4c00250","article-title":"Structure-activity relationship of potent, selective, and orally bioavailable molecular glue degraders of CK1\u03b1","volume":"15","author":"Nishiguchi","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118821_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118821_bb0170","doi-asserted-by":"crossref","first-page":"16953","DOI":"10.1021\/acs.jmedchem.3c01736","article-title":"Design and development of IKZF2 and CK1\u03b1 dual degraders","volume":"66","author":"Miyamoto","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0175","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1021\/jacsau.4c00762","article-title":"Development of oral, potent, and selective CK1\u03b1 degraders for AML therapy","volume":"4","author":"Huang","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.bmc.2026.118821_bb0180","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2767-9764.CRC-23-0264","article-title":"FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1\/3 and CK1\u03b1 to activate p53 and inhibit NF\u03baB signaling","volume":"4","author":"Kanaoka","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0190","series-title":"Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith","author":"Baculi","year":"2020"},{"key":"10.1016\/j.bmc.2026.118821_bb0185","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1021\/acs.jmedchem.1c01832","article-title":"Development of PDE6D and CK1\u03b1 degraders through chemical derivatization of FPFT-2216","volume":"65","author":"Teng","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0195","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2024-209924","article-title":"BMS-986397, a first-in-class molecular glue degrader of casein kinase 1\u03b1 (CK1\u03b1) for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) harboring functional TP53","volume":"144","author":"Jimenez","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2026.118821_bb0200","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2024-210023","article-title":"Synergistic activity of BMS-986397, a first-in-class a Cereblon (CRBN) E3 ligase modulator (CELMoD) targeting casein kinase 1\u03b1 (CK1\u03b1), in combination with venetoclax and\/or azacitidine in preclinical models of acute myeloid leukemia (AML)","volume":"144","author":"Jimenez","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2026.118821_bb0205","article-title":"Selective and potent molecular glue degraders for NIMA-related kinase 7","volume":"64","author":"Chen","year":"2025","journal-title":"Angew Chem Int Ed Eng"},{"key":"10.1016\/j.bmc.2026.118821_bb0210","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"\"magic chloro\": profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s42004-025-01641-9","article-title":"Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC","volume":"8","author":"Glaza","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0220","series-title":"WEE1 degrading compounds and uses thereof (WO patent no. 2024\/006881 A1)","author":"Sapienza","year":"2024"},{"key":"10.1016\/j.bmc.2026.118821_bb0225","first-page":"24","article-title":"Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer","volume":"6","author":"Asciolla","year":"2025","journal-title":"Nat Can"},{"key":"10.1016\/j.bmc.2026.118821_bb0230","series-title":"Compounds that mediate protein degradation and methods of use thereof (WO patent no. 2023\/069700 A1)","author":"Fasching","year":"2023"},{"key":"10.1016\/j.bmc.2026.118821_bb0235","series-title":"Compounds that mediate protein degradation and methods of use thereof (WO patent no. 2023\/069720 A1)","author":"Fasching","year":"2023"},{"key":"10.1016\/j.bmc.2026.118821_bb0240","series-title":"Compounds that Mediate Protein Degradation and Methods of Use Thereof (WO Patent No. 2024\/092039 A1)","author":"Ritz\u00e9n","year":"2024"},{"key":"10.1016\/j.bmc.2026.118821_bb0245","series-title":"Compounds that mediate protein degradation and methods of use thereof (WO patent no. 2025\/090727 A1)","author":"Ritz\u00e9n","year":"2025"},{"key":"10.1016\/j.bmc.2026.118821_bb0250","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-LB422","article-title":"Abstract LB422: selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive\/HER2-negative breast cancer","volume":"85","author":"Gkountela","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118821_bb0255","doi-asserted-by":"crossref","first-page":"15996","DOI":"10.1021\/acs.jmedchem.6c01264","article-title":"Selective CDK2 degradation via noncanonical recruitment","volume":"69","author":"Pei","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.chembiol.2018.10.015","article-title":"Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition","volume":"26","author":"Wood","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2026.118821_bb0265","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bbrc.2023.04.026","article-title":"Structural basis of CDK3 activation by cyclin E1 and inhibition by dinaciclib","volume":"662","author":"Gui","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0285","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/prot.21633","article-title":"Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck\/imatinib complex","volume":"70","author":"Jacobs","year":"2008","journal-title":"Proteins"},{"key":"10.1016\/j.bmc.2026.118821_bb0290","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/384484a0","article-title":"Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation","volume":"384","author":"Yamaguchi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0280","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.2025031127","article-title":"LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia","volume":"148","author":"Yoshimura","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2026.118821_bb0270","doi-asserted-by":"crossref","first-page":"19560","DOI":"10.1021\/acs.jmedchem.6c00996","article-title":"Accelerate your science: direct-to-biology strategies in medicinal chemistry","volume":"69","author":"Hiesinger","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118821_bb0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1021\/jacs.5c13496","article-title":"Direct-to-biology enabled molecular glue discovery","volume":"148","author":"Hu","year":"2026","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2026.118821_bb0295","series-title":"Anaplastic lymphoma kinase (ALK) degraders and uses thereof (WO patent no. 2026\/035999 A1)","author":"La","year":"2026"},{"key":"10.1016\/j.bmc.2026.118821_bb0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-026-10998-3","article-title":"TRI-611, a selective, brain-penetrant molecular glue degrader of ALK","volume":"658","author":"Conery","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0310","series-title":"Compounds for the degradation of ALK proteins (WO patent no. 2025\/221826 A1)","author":"Cortez","year":"2025"},{"key":"10.1016\/j.bmc.2026.118821_bb0305","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1158\/1538-7445.AM2025-6378","article-title":"Abstract 6378: brain-penetrant molecular glue degraders targeting ALK via a novel degron: a potential therapeutic approach for ALK-positive NSCLC","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118821_bb0315","article-title":"Developing potent and selective TBK1 molecular glue degraders for cancer immunotherapy","author":"Caldwell","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.bmc.2026.118821_bb0320","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41586-019-1000-2","article-title":"Structural basis of STING binding with and phosphorylation by TBK1","volume":"567","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118821_bb0325","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbrc.2021.02.110","article-title":"Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma","volume":"549","author":"Zhao","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2026.118821_bb0335","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nsmb.1628","article-title":"Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1","volume":"16","author":"Yun","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2026.118821_bb0330","article-title":"Discovery of CDK4-selective molecular glue degraders by high-throughput proteomics","author":"Zanon","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.bmc.2026.118821_bb0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.omto.2020.06.013","article-title":"A cereblon modulator CC-885 induces CRBN- and p97-dependent PLK1 degradation and synergizes with volasertib to suppress lung cancer","volume":"18","author":"Li","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.bmc.2026.118821_bb0345","doi-asserted-by":"crossref","unstructured":"B. Shashikadze, I. Scheller, D. Winkler, P.R.A. Zanon, A. Bednarz, D. Bartoschek, S. Machata, T. Graef, U. Ohmayer, B. Schwalb, H. Daub, M. Steger, Integrated proteomic screening reveals design principles of CRBN molecular glue degraders, bioRxiv, (2026) 2026.2003.2008.710269. 10.64898\/2026.03.08.710269.","DOI":"10.64898\/2026.03.08.710269"},{"key":"10.1016\/j.bmc.2026.118821_bb0350","doi-asserted-by":"crossref","unstructured":"H. Lin, X. Yu, H. Zheng, R. Cheng, M. Zhang, X. Qi, Y.-Y. Yang, S. Zhou, S. Yesylevskyy, A. Nafiiev, X. Che, J. Wang, Leveraging high-throughput proteomics and AI-based protein folding to accelerate VAV1 molecular glue discovery, bioRxiv, (2026) 2025.2006.2008.658535. https:\/\/doi.org\/10.1101\/2025.06.08.658535.","DOI":"10.1101\/2025.06.08.658535"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:21:32Z","timestamp":1792056092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":70,"alternative-id":["S0968089626002774"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118821","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent discoveries of CRBN-binding molecular glue degraders: Focus on protein kinases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118821"}}